OBJECTIVE To study mood disturbance in Graves ophthalmopathy. METHODS Forty-eight patients (mean age, 55 years; 40 women and 8 men) with Graves ophthalmopathy from a university-based referral center were classified into two groups, 24 with moderate/severe disease (study group) and 24 with negligible/mild disease (control group). The groups were matched with regard to demographic and medical c...

AIMS To determine quality of life and adequacy of education and counselling in Australian patients with Graves' ophthalmopathy during the course of their illness. METHODS A cross sectional study was conducted at the orbital and endocrinology clinics of Royal Brisbane Hospital on 162 consecutive patients with Graves' ophthalmopathy who were managed between the 1992 and 2000. The Graves' ophtha...

Aims: To determine quality of life and adequacy of education and counselling in Australian patients with Graves’ ophthalmopathy during the course of their illness. Methods: A cross sectional study was conducted at the orbital and endocrinology clinics of Royal Brisbane Hospital on 162 consecutive patients with Graves’ ophthalmopathy who were managed between the 1992 and 2000. The Graves’ ophtha...

OBJECTIVE The aim of this study was to clarify whether Tc-99m HIG (Polyclonal Human Immunoglobulin G) can image and determine the severity of orbital involvement in patients with Graves' ophthalmopathy. MATERIALS AND METHODS Twenty-six patients between 19 and 56 years old with Graves' ophthalmopathy were examined. All patients received approximately 370 MBq Tc-99m HIG by i.v. injection. Plana...

Cigarette smoking is the most important risk factor for the development or deterioration of Graves' ophthalmopathy. Smoke-induced increased generation of reactive oxygen species may be involved. However, it remains to be clarified how orbital fibroblasts are affected by cigarette smoking. Our study demonstrated that Graves' orbital fibroblasts have exaggerated response to cigarette smoke extrac...

PURPOSE To assess the self-esteem of Graves' ophthalmopathy patients in the inactive phase. METHODS Thirty euthyroid patients were evaluated in the inactive phase of disease with age ranging from 26 to 65 years, average of 43 +/- 11,0 years, called study group and 39 individuals without Graves' ophthalmopathy with age ranging from 18 to 67 years, average of 41 +/- 13,4 years, selected from th...

Exophthalmos makes up a clinical manifestation very frequent in Graves’ disease. European Group on Graves’ Orbitopathy proposes intravenous glucocorticoids to treat severe, moderate-to-severe and active Graves’ orbitopathy as the first line treatment. The aim of our study is to report results obtained with patients treated for Graves’ ophthalmopathy with this protocol in real life. It is a desc...

AIM To assess levels of soluble Fas (sFas) in the sera of patients with Graves' ophthalmopathy. METHODS The subjects in this study were 43 patients with Graves' ophthalmopathy and 11 normal subjects. Serum levels of sFas were determined by sandwich enzyme linked immunosorbent assay. In addition, serum levels of thyroid stimulating antibody (TSAB) were also measured in all the patients. RESU...

Graves' disease is an autoimmune disorder, caused by thyroid-stimulating antibodies, which bind to and activate the thyrotropin receptor on thyroid cells, inducing the synthesis and release of thyroid hormones. It is a polygenic and multifactorial disease that develops as a result of complex interaction between genetic susceptibility and environmental and/or endogenous factors. Graves' disease ...